Top

European Archives of Psychiatry and Clinical Neuroscience

Open Access 26-04-2024 | Original Paper

Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study

Authors: Camilla Ricci, Emanuela Leuci, Emanuela Quattrone, Derna Palmisano, Pietro Pellegrini, Marco Menchetti, Simona Pupo, Lorenzo Pelizza

Published in: European Archives of Psychiatry and Clinical Neuroscience

Abstract

Negative symptoms in CHR-P people are generally not responsive to treatments and commonly related to poorer functional outcome. However, less research attention has been dedicated to Persistent Negative Symptoms (PNS), defined as clinically stable negative symptoms of moderate severity evident for at least 6 months. This study aims to (a) determine the prevalence of PNS in a sample of young people at CHR-P; (b) investigate any association of PNS with functioning and clinical features; (c) examine longitudinal course of PNS across 2 years of follow-up and changes in PNS severity levels with specialized treatments. One Hundred Eighty CHR-P participants were recruited and were divided into CHR-P/PNS + and CHR-P/PNS− subgroups. The clinical assessments were based on the PANSS and the GAF and were conducted at baseline and every 12 months during the follow-up. Twenty four participants showed PNS at entry. Of them, 21 concluded the 2-year follow-up period. At baseline, the CHR-P/PNS + participants showed more educational and employment deficits, and more social and functioning impairment. During the follow-up, the CHR-P/PNS + subgroup had a significant longitudinal decrease in negative symptoms, which was specifically related to antidepressant treatment. CHR-P/PNS + subjects also showed a higher incidence of new hospitalization and a lower functional recovery over time. Our findings support that the persistence of negative symptoms in CHR-P people is longitudinally related to worse daily functioning and more severe clinical conditions that are at higher risk of hospitalization and are less responsive to specialized treatments.

Available only for authorised users

Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, McGuire PK (2013) Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med 43:2311–2325. https://doi.org/10.1017/S0033291713000251CrossRefPubMed

Lim K, Rapisarda A, Keefe RSE, Lee J (2022) Social skills, negative symptoms and real-world functioning in individuals at ultra-high risk of psychosis. Asian J Psychiatr 69:102996. https://doi.org/10.1016/j.ajp.2021.102996CrossRefPubMed

Millan MJ, Fone K, Steckler T, Horan WP (2014) Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24:645–692. https://doi.org/10.1016/j.euroneuro.2014.03.008CrossRefPubMed

Aleman A, Lincoln T, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H (2017) Treatment of negative symptoms: where do we stand, and where do we go? Schizophr Res 186:55–62. https://doi.org/10.1016/j.schres.2016.05.015CrossRefPubMed

Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, Broussard C, Pantelis C, Yung AR (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 132:1–7. https://doi.org/10.1016/j.schres.2011.06.014CrossRefPubMed

Yung AR, Cotter J, Wood SJ, McGorry P, Thompson AD, Nelson B, Lin A (2015) Childhood maltreatment and transition to psychotic disorder independently predict long term functioning in young people at ultra high risk for psychosis. Psychol Med 45:3453–3465. https://doi.org/10.1017/s003329171500135xCrossRefPubMed

Tran T, Spilka MJ, Raugh IM, Strauss GP, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Walker EF, Woods SW, Addington JM (2023) Negative symptom trajectories in individuals at clinical high risk for psychosis: differences based on deficit syndrome, persistence, and transition status. Schizophr Bull Open 4:sgad014. https://doi.org/10.1093/schizbullopen/sgad014CrossRefPubMedPubMedCentral

Sauvé G, Brodeur MB, Shah JL, Lepage M (2019) The prevalence of negative symptoms across the stages of the psychosis continuum. Harv Rev Psychiatry 27:15–32. https://doi.org/10.1097/HRP.0000000000000184CrossRefPubMed

Buchanan RW (2007) Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33:1013–1022. https://doi.org/10.1093/schbul/sbl057CrossRefPubMed

10.

Devoe LDJ, Lu TD, Cannon KS, Cadenhead BA, Cornblatt TH, McGlashan DO, Perkins LJ, Seidman MT, Tsuang SW, Woods EF, Walker DH, Mathalon CE, Bearden J, Addington J (2021) Persistent negative symptoms in youth at clinical high risk for psychosis: a longitudinal study. Schizophr Res 227:28–37. https://doi.org/10.1016/j.schres.2020.04.004CrossRefPubMed

11.

Pelizza L, Leuci E, Quattrone E, Azzali S, Paulillo G, Pupo S, Pellegrini P, Menchetti M (2023) Longitudinal evaluation on negative symptoms in young people at ultra-high risk (UHR) of psychosis: results from a 2-year follow-up study in a real-world care setting. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-023-01600-2CrossRefPubMed

12.

Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, Giordano GM, Vandevelde A, Nielsen MØ, Glenthøj LB, Sabé M, Pezzella P, Bitter I, Gaebel W (2021) EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 64(1):e23. https://doi.org/10.1192/j.eurpsy.2021.11CrossRefPubMedPubMedCentral

13.

Chang W, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY (2011) Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res 133:22–28. https://doi.org/10.1016/j.schres.2011.09.006CrossRefPubMed

14.

Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker W, Kahn RS (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial. Eur Neuropsychopharmacol 23:196–204. https://doi.org/10.1016/j.euroneuro.2012.04.019CrossRefPubMed

15.

Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:224. https://doi.org/10.1186/1471-244x-12-224CrossRefPubMedPubMedCentral

16.

Puig O, Baeza I, de la Serna E, Cabrera B, Mezquida G, Bioque M, Lobo A, Gonzalez-Pinto A, Parellada M, Corripio I, Vieta E, Bobes J, Usall J, Contreras F, Cuesta MJ, Bernardo M, Castro-Fornieles J (2017) Persistent negative symptoms in first-episode psychosis: early cognitive and social functioning correlates and differences between early and adult onset. J Clin Psychiatry 78:1414–1422. https://doi.org/10.4088/jcp.16m11122CrossRefPubMed

17.

Edwards J, McGorry PD, Waddell FM, Harrigan SM (1999) Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophr Res 40:147–158. https://doi.org/10.1016/s0920-9964(99)00043-2CrossRefPubMed

18.

Yung AR, Nelson B, McGorry PD, Wood SJ, Lin A (2018) Persistent negative symptoms in individuals at ultra high risk for psychosis. Schizophr Res 206:355–361. https://doi.org/10.1016/j.schres.2018.10.019CrossRefPubMed

19.

Devoe DJ, Lu L, Cannon TD, Cadenhead KS, Cornblatt BA, Keshavan M, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Woods SW, Walker EF, Mathalon DH, Bearden CE, Addington J (2023) The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis. Front Psychiatry 14:1125168. https://doi.org/10.3389/fpsyt.2023.1125168CrossRefPubMedPubMedCentral

20.

Pelizza L, Leuci E, Maestri D, Quattrone E, Azzali S, Paulillo G, Pellegrini P (2022) Longitudinal persistence of negative symptoms in young individuals with first episode schizophrenia: a 24-month multi-modal program follow-up. Nord J Psychiatry 76:530–538. https://doi.org/10.1080/08039488.2021.2015431CrossRefPubMed

21.

Pelizza L, Leuci E, Quattrone E, Paulillo G, Pellegrini P (2023) The “parma at-risk mental states” (PARMS) program: general description and process analysis after 5 years of clinical activity. Early Interv Psychiatry 17:625–635. https://doi.org/10.1111/eip.13399CrossRefPubMed

22.

Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell’Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 39:964–971. https://doi.org/10.1080/j.1440-1614.2005.01714.xCrossRefPubMed

23.

Pelizza L, Azzali S, Paterlini F, Garlassi S, Scazza I, Chiri LR, Poletti M, Pupo S, Raballo A (2021) Anhedonia in the psychosis risk syndrome: state and trait characteristics. Psychiatr Danub 33:36–47. https://doi.org/10.24869/psyd.2021.36CrossRefPubMed

24.

Pelizza L, Poletti M, Azzali S, Garlassi S, Scazza I, Paterlini F, Chiri LR, Pupo S, Raballo A (2021) Subjective experience of social cognition in young people at ultra-high risk of psychosis: a 2-year longitudinal study. Nord J Psychiatry 75:97–108. https://doi.org/10.1080/08039488.2020.1799430CrossRefPubMed

25.

Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A (1998) Health of the nation outcome scales (HoNOS): research and development. Br J Psychiatry 172:11–18. https://doi.org/10.1192/bjp.172.1.11CrossRefPubMed

26.

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276. https://doi.org/10.1093/schbul/13.2.261CrossRefPubMed

27.

American Psychiatric Association (APA) (2013) Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). APA Press, ArlingtonCrossRef

28.

Raballo A, Semrov E, Bonner Y, Simmons M (2013) Traduzione e adattamento della CAARMS (comprehensive assessment of at-risk mental states). Centro Stampa della Regione Emilia-Romagna, Bologna

29.

Pelizza L, Paterlini F, Azzali S, Garlassi S, Scazza I, Pupo S, Simmons M, Nelson B, Raballo A (2019) The approved Italian version of the comprehensive assessment of at-risk mental states (CAARMS-ITA): field test and psychometric features. Early Interv Psychiatry 13:810–817. https://doi.org/10.1111/eip.12669CrossRefPubMed

30.

Belvederi Murri M, Ferrara M, Imbesi M, Leuci E, Marchi M, Musella V, Natali A, Neri A, Ragni S, Saponaro A, Tarricone I, Tullini A, Starace F, Early Psychosis Working Group (2022) A public early intervention approach to first-episode psychosis: treated incidence over 7 years in the Emilia-Romagna region. Early Interv Psychiatry 17:724–736. https://doi.org/10.1111/eip.13437CrossRef

31.

Wing J, Curtis RH, Beevor A (1999) Health of the nation outcome scales (HoNOS): glossary for HoNOS score sheet. Br J Psychiatry 174:432–434. https://doi.org/10.1192/bjp.174.5.432CrossRefPubMed

32.

Kortrijk HE, Mulder CL, Drukker M, Wiersma D, Duivenvoorden HJ (2012) Duration of assertive community treatment and the interpretation of routine outcome data. Aust N Z J Psychiatry 46:240–248. https://doi.org/10.1177/0004867411433214CrossRefPubMed

33.

Leuci E, Pelizza L, Landi G, Quattrone E, Maestri D, Azzali S, Pelosi A, Ceroni P, Soncini C, Daolio MC, Paulillo G, Raballo A, Pellegrini P (2022) Personal health budget in patients with first episode psychosis: a new rehabilitation model based on a community care system in Italy. Early Interv Psychiatry 16:221–230. https://doi.org/10.1111/eip.13145CrossRefPubMed

34.

Scazza I, Pelizza L, Azzali S, Garlassi S, Paterlini F, Chiri LR, Poletti M, Pupo S, Raballo A (2022) Aberrant salience in first-episode psychosis: Longitudinal stability and treatment-response. Early Interv Psychiatry 16:912–919. https://doi.org/10.1111/eip.13243CrossRefPubMed

35.

Shafer A, Dazzi F (2019) Meta-analysis of the positive and negative syndrome scale (PANSS) factor structure. J Psychiatr Res 115:113–120. https://doi.org/10.1016/j.jpsychires.2019.05.008CrossRefPubMed

36.

Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449. https://doi.org/10.1176/appi.ajp.162.3.441CrossRefPubMed

37.

Zhang TH, Li HJ, Woodberry KA, Xu LH, Tang YY, Guo Q, Cui HR, Liu XH, Chow A, Li CB, Jiang KD, Xiao ZP, Seidman LJ, Wang JJ (2017) Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion. Epidemiol Psychiatr Sci 26:287–298. https://doi.org/10.1017/S2045796016000184CrossRefPubMed

38.

Pelizza L, Leuci E, Quattrone E, Azzali S, Pupo S, Paulillo G, Menchetti M, Pellegrini P (2023) Adverse outcome analysis in people at clinical high risk for psychosis: results from a 2-year Italian follow-up study. Soc Psychiatry Psychiatr Epidemiol. https://doi.org/10.1007/s00127-023-02597-8CrossRefPubMed

39.

Azzali S, Pelizza L, Scazza I, Paterlini F, Garlassi S, Chiri LR, Poletti M, Pupo S, Raballo A (2022) Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: a 1-year longitudinal study. Schizophr Res 241:52–58. https://doi.org/10.1016/j.schres.2021.12.025CrossRefPubMed

40.

Yang H, Gao S, Li J, Yu H, Xu J, Lin C, Yang H, Teng C, Ma H, Zhang N (2022) Remission of symptoms is not equal to functional recovery: psychosocial functioning impairment in major depression. Front Psychiatry 13:915689. https://doi.org/10.3389/fpsyt.2022.915689CrossRefPubMedPubMedCentral

41.

Schultze-Lutter F, Rahman J, Ruhrmann S, Michel C, Schimmelmann BG, Maier W, Klosterkötter J (2015) Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. Soc Psychiatry Psychiatr Epidemiol 50:1831–1841. https://doi.org/10.1007/s00127-015-1093-3CrossRefPubMed

42.

Silverman MM, Berman AL, Sanddal ND, O’carroll PW, Joiner TE (2007) Rebuilding the tower of Babel: a revised nomenclature for the study of suicide and suicidal behaviors—part 2: suicide-related ideations, communications, and behaviors. Suicide Life Threat Behav 37:264–277. https://doi.org/10.1521/suli.2007.37.3.264CrossRefPubMed

43.

Robson E, Greenwood K (2022) Rates and predictors of disengagement and strength of engagement for people with a first episode of psychosis using early intervention services: a systematic review of predictors and meta-analysis of disengagement rates. Schizophr Bull Open 3:sgac012. https://doi.org/10.1093/schizbullopen/sgac012CrossRef

44.

Pelizza L, Maestri D, Leuci E, Quattrone E, Azzali S, Paulillo G, Pellegrini P (2022) Individual psychotherapy can reduce suicidal ideation in first episode psychosis: further findings from the 2-year follow-up of the “Parma Early Psychosis” programme. Clin Psychol Psychother 29:982–989. https://doi.org/10.1002/cpp.2678CrossRefPubMed

45.

Silva MA, Restrepo D (2019) Functional recovery in schizophrenia. Rev Colomb Psiquiatr 48:252–260. https://doi.org/10.1016/j.rcp.2017.08.004CrossRef

46.

First MB, Williams JBW, Karg RS, Spitzer RL (2016) SCID-5-CV. Structured clinical interview for DSM-5 mental disorders, Clinical Version. American Psychiatric Association Publishing, Washington DC

47.

Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404. https://doi.org/10.1016/j.eurpsy.2015.01.013CrossRefPubMed

48.

Regione Emilia-Romagna (RER) (2023) Raccomandazioni regionali per la promozione della salute e del benessere in persone all’esordio psicotico, seconda edizione. Centro Stampa della Regione Emilia-Romagna, Bologna.

49.

Poletti M, Azzali S, Paterlini F, Garlassi S, Scazza I, Chiri LR, Pupo S, Raballo A, Pelizza L (2021) Familiarity for serious mental illness in help-seeking adolescents at clinical high risk of psychosis. Front Psychiatry 11:552282. https://doi.org/10.3389/fpsyt.2020.552282CrossRefPubMedPubMedCentral

50.

van der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RM, Koeter M, Cuijpers P, Wunderink L, Linszen DH (2012) Cognitive behavioral therapy for subjects at ultra-high risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 38:1180–1188. https://doi.org/10.1093/schbul/sbs105CrossRefPubMedPubMedCentral

51.

McFarlane WR (2016) Family interventions for schizophrenia and the psychoses: a review. Fam Process 55:460–482. https://doi.org/10.1111/famp.12235CrossRefPubMed

52.

Poletti M, Pelizza L, Azzali S, Garlassi S, Scazza I, Paterlini F, Chiri LR, Pupo S, Raballo A (2022) Subjective experience of aberrant salience in young people at ultra-high risk (UHR) for psychosis: a cross-sectional study. Nord J Psychiatry 76:129–137. https://doi.org/10.1080/08039488.2021aCrossRefPubMed

53.

Ficarelli ML, Troisi E, Vignali E, Artoni S, Franzini MC, Montanaro S, Andreoli MV, Marangoni S, Ciampà E, Erlicher D, Pupo S, Pelizza L (2021) Implementing individual and placement support for patients with severe mental illness: findings from the real world. J Psychopathol 27:71–80

54.

SPSS Inc (2010) Statistical Package for Social Science, version 15.0 for Windows. SPSS Press, Chicago (IL)

55.

Ver Hoef JM (2012) Who invented the delta method? Am Statist 66:124–127. https://doi.org/10.1080/00031305.2012.687494CrossRef

56.

Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM (2018) Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 6:121. https://doi.org/10.21037/atm.2018.02.12CrossRefPubMedPubMedCentral

57.

Harris JK (2021) Primer on binary logistic regression. Fam Med Community Health 9(Suppl. 1):e001290. https://doi.org/10.1136/fmch-2021-001290CrossRefPubMedPubMedCentral

58.

Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37:300–305. https://doi.org/10.1093/schbul/sbq059CrossRefPubMed

59.

Ucok A, Ergul C (2014) Persistent negative symptoms after first episode schizophrenia: a 2-year follow-up study. Schizophr Res 158:241–246. https://doi.org/10.1016/j.schres.2014.07.021CrossRefPubMed

60.

Bleuler E (1911) Dementia Praecox oder Gruppe der Schizophrenien. Verlag, Leipzig

61.

Pelizza L, Poletti M, Azzali S, Garlassi S, Scazza I, Paterlini F, Chiri LR, Pupo S, Raballo A (2020) Subjective experience of social cognition in adolescents at ultra-high risk of psychosis: findings from a 24-month follow-up study. Eur Child Adolesc Psychiatry 29:1645–1657. https://doi.org/10.1007/s00787-020-01482-yCrossRefPubMed

62.

Jang SK, Choi HI, Park S, Jaekal E, Lee GY, Cho YI, Choi KH (2026) A two-factor model better explains heterogeneity in negative symptoms: evidence from the positive and negative syndrome scale. Front Psychol 7:707. https://doi.org/10.3389/fpsyg.2016.00707CrossRef

63.

Okada H, Hirano D, Taniguchi T (2021) Impact of negative symptom domains and other clinical characteristics on functional outcomes in patients with schizophrenia. Schizophr Res Treatment 2021:8864352. https://doi.org/10.1155/2021/8864352CrossRefPubMedPubMedCentral

64.

Barnes TR, Leeson VC, Paton C, Costelloe C, Simon J, Kiss N, Osborn D, Killaspy H, Craig TK, Lewis S, Keown P, Ismail S, Crawford M, Baldwin D, Lewis G, Geddes J, Kumar M, Pathak R, Taylor S (2016) Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technol Assess 20:1–46. https://doi.org/10.3310/hta20290.PMID:27094189;PMCID:PMC4860560CrossRefPubMedPubMedCentral

65.

Phan SV, Kreys TJ (2011) Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy 31:1017–1030. https://doi.org/10.1592/phco.31.10.1017CrossRefPubMed

66.

Murphy SE, Capitão LP, Giles SLC, Cowen PJ, Stringaris A, Harmer CJ (2021) The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry 8:824–835. https://doi.org/10.1016/S2215-0366(21)00154-1CrossRefPubMed

67.

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927–942. https://doi.org/10.1176/appi.ajp.2017.16121358CrossRefPubMed

68.

Correll CU, Schooler NR (2020) Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 16:519–534. https://doi.org/10.2147/NDT.S225643CrossRefPubMedPubMedCentral

69.

Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268:625–639. https://doi.org/10.1007/s00406-018-0869-3CrossRefPubMed

70.

Veerman SRT, Schulte PFJ, de Haan L (2017) Treatment for negative symptoms in schizophrenia: a comprehensive review. Drugs 77:1423–1459. https://doi.org/10.1007/s40265-017-0789-yCrossRefPubMed

71.

Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J, Weiser M, Luthringer R (2017) Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry 174:1195–1202. https://doi.org/10.1176/appi.ajp.2017.17010122CrossRefPubMed

72.

Beck AT, Grant PM, Huh GA, Perivoliotis D, Chang NA (2013) Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. Schizophr Bull 39:43–51. https://doi.org/10.1093/schbul/sbr040CrossRefPubMed

73.

Turner DT, van der Gaag M, Karyotaki E, Cuijpers P (2014) Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry 171:523–538. https://doi.org/10.1176/appi.ajp.2013.13081159CrossRefPubMed

74.

Elis O, Caponigro JM, Kring AM (2013) Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev 33:914–928. https://doi.org/10.1016/j.cpr.2013.07.001CrossRefPubMedPubMedCentral

75.

Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204:20–29. https://doi.org/10.1192/bjp.bp.112.116285CrossRefPubMed

76.

Kaiser S, Lyne J, Agartz I, Clarke M, Mørch-Johnsen L, Faerden A (2017) Individual negative symptoms and domains: relevance for assessment, pathomechanisms and treatment. Schizophr Res 186:39–45. https://doi.org/10.1016/j.schres.2016.07.013CrossRefPubMed

77.

Pelizza L, Leuci E, Quattrone E, Azzali S, Paulillo G, Pupo S, Poletti M, Raballo A, Pellegrini P, Menchetti M (2023) Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: findings from the Parma at-risk mental states (PARMS) program. Early Interv Psychiatry. https://doi.org/10.1111/eip.13434CrossRefPubMed

78.

Bucci P, Mucci A, van Rossum IW, Aiello C, Arango C, Baandrup L, Buchanan RW, Dazzan P, Demjaha A, Díaz-Caneja CM, Giordano GM, Glenthøj BY, Leucht S, McGuire P, Rodriguez-Jimenez R, Vignapiano A, Kahn RS, Galderisi S (2020) Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning. Eur Neuropsychopharmacol 34:76–86. https://doi.org/10.1016/j.euroneuro.2020.03.010CrossRefPubMed

79.

Strauss GP, Pelletier-Baldelli A, Visser KF, Walker EF, Mittal VA (2020) A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis. Schizophr Res 222:104–112. https://doi.org/10.1016/j.schres.2020.04.019CrossRefPubMedPubMedCentral

80.

Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, Sear V, Rocchetti M, De Micheli A, Jones C, Palombini E, McGuire P, Fusar-Poli P (2016) Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra-high risk for psychosis. J Affect Disord 203:101–110. https://doi.org/10.1016/j.jad.2016.05.053CrossRefPubMed

81.

Yang Z, Lim K, Lam M, Keefe R, Lee J (2018) Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra-high risk (UHR) for psychosis. Schizophr Res 201:85–90. https://doi.org/10.1016/j.schres.2018.05.024CrossRefPubMed

82.

Barch DM (2013) The CAINS: theoretical and practical advances in the assessment of negative symptoms in schizophrenia. Am J Psychiatry 170:133–135. https://doi.org/10.1176/appi.ajp.2012.12101329CrossRefPubMed

83.

Strauss GP, Walker EF, Pelletier-Baldelli A, Carter NT, Ellman LM, Schiffman J, Luther L, James SH, Berglund AM, Gupta T, Ristanovic I, Mittal VA (2023) Development and validation of the negative symptom inventory-psychosis risk. Schizophr Bull 49:1205–1216. https://doi.org/10.1093/schbul/sbad038CrossRefPubMedPubMedCentral

84.

Carrión RE, Auther AM, McLaughlin D, Olsen R, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cornblatt BA (2019) The global functioning: social and role scales: further validation in a large sample of adolescents and young adults at clinical high risk for psychosis. Schizophr Bull 45:763–772. https://doi.org/10.1093/schbul/sby126CrossRefPubMed

85.

Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabé M, Giordano GM, Nielsen MØ, Glenthøj LB, Pezzella P, Falkai P, Dollfus S, Gaebel W (2021) EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry 64:e21. https://doi.org/10.1192/j.eurpsy.2021.13CrossRefPubMedPubMedCentral

Title: Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study
Authors: Camilla Ricci
Emanuela Leuci
Emanuela Quattrone
Derna Palmisano
Pietro Pellegrini
Marco Menchetti
Simona Pupo
Lorenzo Pelizza
Publication date: 26-04-2024
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-024-01808-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Persistent negative symptoms in young people at clinical high risk of psychosis treated with an Italian early intervention program: a longitudinal study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content